159 related articles for article (PubMed ID: 23545708)
21. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-like peptide-1 is a physiological incretin in rat.
Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
[TBL] [Abstract][Full Text] [Related]
23. GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide.
Elahi D; Egan JM; Shannon RP; Meneilly GS; Khatri A; Habener JF; Andersen DK
Obesity (Silver Spring); 2008 Jul; 16(7):1501-9. PubMed ID: 18421270
[TBL] [Abstract][Full Text] [Related]
24. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
25. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
Deacon CF; Plamboeck A; Møller S; Holst JJ
Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E873-9. PubMed ID: 11882507
[TBL] [Abstract][Full Text] [Related]
26. [Influences of exendin-4 on the secretion function of islet beta cells from rats in the early stage of severe scald].
Zhao DX; Ma L; Shen ZA; Li DW; Shang YR; Yin K; Cheng WF; Wang X; Liu ZX
Zhonghua Shao Shang Za Zhi; 2016 Dec; 32(12):752-758. PubMed ID: 28043300
[No Abstract] [Full Text] [Related]
27. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.
D'Alessio DA; Vogel R; Prigeon R; Laschansky E; Koerker D; Eng J; Ensinck JW
J Clin Invest; 1996 Jan; 97(1):133-8. PubMed ID: 8550824
[TBL] [Abstract][Full Text] [Related]
28. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Metabolism; 2004 Feb; 53(2):252-9. PubMed ID: 14767880
[TBL] [Abstract][Full Text] [Related]
29. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
30. Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes.
Wang L; Guo F; Wei S; Zhao R
Peptides; 2011 Jun; 32(6):1313-9. PubMed ID: 21453734
[TBL] [Abstract][Full Text] [Related]
31. Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas.
Fehmann HC; Göke R; Göke B; Bächle R; Wagner B; Arnold R
Biochim Biophys Acta; 1991 Feb; 1091(3):356-63. PubMed ID: 1705823
[TBL] [Abstract][Full Text] [Related]
32. Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion.
Witte AB; Grybäck P; Jacobsson H; Näslund E; Hellström PM; Holst JJ; Hilsted L; Schmidt PT
Scand J Gastroenterol; 2011 Apr; 46(4):428-35. PubMed ID: 21114428
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
34. Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass.
Shah M; Law JH; Micheletto F; Sathananthan M; Dalla Man C; Cobelli C; Rizza RA; Camilleri M; Zinsmeister AR; Vella A
Diabetes; 2014 Feb; 63(2):483-93. PubMed ID: 24089513
[TBL] [Abstract][Full Text] [Related]
35. Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes.
Vella A; Shah P; Basu R; Basu A; Camilleri M; Schwenk FW; Holst JJ; Rizza RA
Diabetes; 2001 Mar; 50(3):565-72. PubMed ID: 11246876
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Sandhu H; Wiesenthal SR; MacDonald PE; McCall RH; Tchipashvili V; Rashid S; Satkunarajah M; Irwin DM; Shi ZQ; Brubaker PL; Wheeler MB; Vranic M; Efendic S; Giacca A
Diabetes; 1999 May; 48(5):1045-53. PubMed ID: 10331409
[TBL] [Abstract][Full Text] [Related]
37. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
38. Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice.
Tudurí E; Beiroa D; Porteiro B; López M; Diéguez C; Nogueiras R
Diabetes Obes Metab; 2015 Aug; 17(8):789-99. PubMed ID: 25962313
[TBL] [Abstract][Full Text] [Related]
39. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
[TBL] [Abstract][Full Text] [Related]
40. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
